• LBP, AMPK and Mitophagy in Muscle Atrophy

  2026-08-28

  A 2025 study shows that Lycium barbarum polysaccharide protects skeletal muscle from high-fat-diet-associated atrophy by engaging AMPK/PINK1/Parkin-mediated mitophagy. Its combination of metabolic, mitochondrial, pharmacological, and Parkin-knockdown evidence supports a mechanistic model linking improved glucose-lipid handling with mitochondrial quality control in sarcopenic obesity.

• UK-5099 (PF-1005023): Mechanism & Uses

  2026-08-28

  UK-5099, also called PF-1005023, is a mitochondrial pyruvate carrier inhibitor that blocks pyruvate entry into mitochondria. Its reported activity supports mitochondrial metabolism research, while cellular and mouse findings connect MPC inhibition with altered energy metabolism and glucose tolerance.

• Difloxacin HCl: A Mechanism-First Research Guide

  2026-08-27

  Difloxacin HCl is a quinolone antimicrobial antibiotic suited to bacterial DNA replication inhibition, antimicrobial susceptibility testing, and multidrug resistance reversal research. This guide connects compound handling and assay design with a mechanistic lesson from Plk1–p31comet checkpoint biology: reliable conclusions depend on matching molecular action to the correct experimental readout.

• QX77: A Decision Framework for Autophagy Assays

  2026-08-27

  QX77 is a molecular chaperone activator for dissecting LAMP2A, Rab11, and autophagy responses without conflating chaperone-mediated autophagy with mitophagy. This article translates recent ETS1–SENP2–HSPA8–FUNDC1 findings into a rigorous assay-design and interpretation framework.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-26

  Masitinib (AB1010), SKU A2942, is a DMSO-compatible phenylaminothiazole kinase inhibitor for studying KIT, PDGFRα, PDGFRβ, selected KIT mutants, and mast-cell responses. It is appropriate for controlled biochemical and cellular research, but not for aqueous or ethanol-based workflows, broad-spectrum kinase screens, or clinical dosing decisions without separate validation.

• Norovirus Co-opts NINJ1 for Selective NS1 Secretion

  2026-08-26

  Song and colleagues show that murine norovirus uses the membrane-rupture factor NINJ1 to release the viral protein NS1 while simultaneously permitting broad damage-associated molecular pattern release. The study combines CRISPR screening, infection models, localization and interaction analyses, viral mutagenesis, and mouse experiments to define an unconventional secretion mechanism with physiological relevance.

• ARCA EGFP mRNA: Workflow and Troubleshooting

  2026-08-25

  ARCA EGFP mRNA provides a direct fluorescence readout for comparing mammalian cell delivery, translation, and lipid nanoparticle performance. This practical guide covers assay design, quantitative controls, protocol parameters, and troubleshooting from routine transfection screens to translational mRNA delivery studies.

• Cisplatin and Cancer Stemness: Assay Design Insights

  2026-08-25

  Cisplatin and CDDP remain powerful tools for studying DNA damage, apoptosis, and chemotherapy resistance. This guide connects cisplatin response testing with oral cancer stemness biology to improve assay interpretation and combination-study design.

• Persistent rDNA Damage and PML-Nucleolar Compartments

  2026-08-24

  Urbancokova and colleagues show that topological stress, RNA polymerase I inhibition, and ribosomal DNA double-strand breaks trigger persistent PML-nucleolar associations. Their experiments connect unresolved rDNA lesions with ATM/ATR signaling, homologous-recombination processing, nucleolar compartmentalization, and eventual cellular senescence.

• Palbociclib (PD0332991) in Cancer Assays

  2026-08-24

  Palbociclib (PD0332991) converts CDK4/6 biology into a practical cell-cycle perturbation workflow for breast cancer research, renal cell carcinoma (RCC) research, and mechanistic oncology studies. This guide connects dose-response design with Rb-based validation, apoptosis readouts, and a new colorectal cancer stemness hypothesis.

• Biotin-HPDP: Reliable Thiol Protein Labeling

  2026-08-23

  This scenario-driven guide explains how Biotin-HPDP (N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide), SKU A8008, can improve thiol-specific protein workflows that complement cell viability, proliferation, and cytotoxicity assays. It covers chemistry, sample compatibility, protocol parameters, streptavidin interpretation, and practical supplier-selection criteria.

• Doxorubicin and the Epigenetic Logic of Resistance

  2026-08-22

  Doxorubicin is more than a cytotoxic benchmark: it is a mechanistic probe for DNA damage, chromatin disruption, and drug resistance. This translational guide connects Adriamycin response with the SMYD2–miR-125b–P-glycoprotein axis in renal cancer research.

• Dacarbazine: Mechanism, Uses, and Research Workflow

  2026-08-22

  Dacarbazine is an antineoplastic chemotherapy drug that produces DNA damage after metabolic activation and methylation of guanine-rich DNA. Its established oncology uses include treatment of malignant melanoma, Hodgkin lymphoma, sarcoma, and selected pancreatic islet-cell tumors, while its use requires supervised administration and structured toxicity management.

• O-propargyl-puromycin (OPP) for Protein Synthesis

  2026-08-21

  O-propargyl-puromycin (OPP) converts a short translation pulse into a measurable readout of nascent protein production, supporting cell-state comparisons that conventional endpoint assays can miss. Its click-chemistry workflow is especially useful for dissecting the translation and mitochondrial phenotypes reported in B-cell immunology.

• GSK2606414: Practical PERK Inhibitor Workflows

  2026-08-20

  Learn how to use GSK2606414 to separate PERK-dependent signaling from broader ER stress effects in cell, zebrafish, and translational disease studies. The guide combines dose planning, pathway readouts, reference-study insights, and troubleshooting for reproducible ER stress research.

8557 records 1/571 page Next 12345 下5页 Last page